Loading
A phase 1 trial of AST-201 run by Aptamer Sciences, Inc., now recruiting.
A Study to Evaluate the Tolerability, Safety, and PK of AST-201 in Patients With GPC3-positive Advanced Solid Tumors is a phase 1 interventional study registered as NCT06687941 by Aptamer Sciences, Inc., with 70 participants planned, started 2025-03-11. Conditions recorded: Neoplasms, Carcinoma, Hepatocellular, Carcinoma, Non-Small-Cell Lung and Liver Neoplasms. Interventions recorded: AST-201.
Shares Aptamer Sciences, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Hepatocellular carcinoma, Metastatic cancer (cancer that has spread), Non-small-cell lung cancer and the tag pipeline.
Shares Hepatocellular carcinoma, Non-small-cell lung cancer and the tag pipeline.
Shares Hepatocellular carcinoma, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Hepatocellular carcinoma, Non-small-cell lung cancer and the tag pipeline.
Shares Hepatocellular carcinoma, Metastatic cancer (cancer that has spread), Non-small-cell lung cancer and the tag pipeline.
Shares Metastatic cancer (cancer that has spread), Non-small-cell lung cancer and the tag pipeline.
Shares Hepatocellular carcinoma, Non-small-cell lung cancer and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/